Protein Kinase Inhibitors
7
2
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
28.6%
2 terminated out of 7 trials
50.0%
-36.5% vs benchmark
14%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
Savolitinib vs. Sunitinib in MET-driven PRCC.
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.